Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19811
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAli, Shayma-
dc.contributor.authorScheffer, Ingrid E-
dc.contributor.authorSadleir, Lynette G-
dc.date2018-11-06-
dc.date.accessioned2018-11-26T00:51:07Z-
dc.date.available2018-11-26T00:51:07Z-
dc.date.issued2019-
dc.identifier.citationDevelopmental medicine and child neurology 2019; 61(1): 13-18-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19811-
dc.description.abstractThere are hundreds of compounds found in the marijuana plant, each contributing differently to the antiepileptic and psychiatric effects. Cannabidiol (CBD) has the most evidence of antiepileptic efficacy and does not have the psychoactive effects of ∆9 -tetrahydrocannabinol. CBD does not act via cannabinoid receptors and its antiepileptic mechanism of action is unknown. Despite considerable community interest in the use of CBD for paediatric epilepsy, there has been little evidence for its use apart from anecdotal reports, until the last year. Three randomized, placebo-controlled, double-blind trials in Dravet syndrome and Lennox-Gastaut syndrome found that CBD produced a 38% to 41% median reduction in all seizures compared to 13% to 19% on placebo. Similarly, CBD resulted in a 39% to 46% responder rate (50% convulsive or drop-seizure reduction) compared to 14% to 27% on placebo. CBD was well tolerated; however, sedation, diarrhoea, and decreased appetite were frequent. CBD shows similar efficacy to established antiepileptic drugs. WHAT THIS PAPER ADDS: Cannabidiol (CBD) shows similar efficacy in the severe paediatric epilepsies to other antiepileptic drugs. Careful down-titration of benzodiazepines is essential to minimize sedation with adjunctive CBD.-
dc.language.isoeng-
dc.titleEfficacy of cannabinoids in paediatric epilepsy.-
dc.typeJournal Article-
dc.identifier.journaltitleDevelopmental medicine and child neurology-
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Paediatrics and Child Health, University of Otago, Wellington, New Zealanden
dc.identifier.affiliationRoyal Children's Hospital, Victoria, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartments of Medicine and Paediatrics, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.affiliationMurdoch Children's Research Institutes, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1111/dmcn.14087-
dc.identifier.orcid0000-0002-9177-4938-
dc.identifier.orcid0000-0002-2311-2174-
dc.identifier.orcid0000-0002-5355-7115-
dc.identifier.pubmedid30402932-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherScheffer, Ingrid E
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptEpilepsy Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.